Mechanisms to explain pancreatic dysfunction in cystic fibrosis.

Med Clin North Am

Pancreas Center, Beth Israel Deaconess Medical Center, Boston, Massachussachusetts, USA.

Published: May 2000

This article focuses on three potential mechanisms by which pancreatic dysfunction occurs in cystic fibrosis. These include (1) obstruction of pancreatic ducts by inspissated plugs, (2) inhibition of endocytosis in acinar cells, and (3) imbalance in membrane lipids in cystic fibrosis regulated cells. Any of these abnormalities alone or in combination may explain the development of pancreatic exocrine insufficiency.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0025-7125(05)70248-0DOI Listing

Publication Analysis

Top Keywords

cystic fibrosis
12
pancreatic dysfunction
8
mechanisms explain
4
pancreatic
4
explain pancreatic
4
dysfunction cystic
4
fibrosis article
4
article focuses
4
focuses three
4
three potential
4

Similar Publications

Cystic fibrosis (CF) is a rare genetic disorder commonly affecting multiple organs such as the lungs, pancreas, liver, kidney, and intestine. Our search focuses on the pathophysiological changes that affect the drugs' absorption, distribution, metabolism, and excretion (ADME). This review aims to identify the ADME data that compares the pharmacokinetics (PK) of different drugs in CF and healthy subjects.

View Article and Find Full Text PDF

Perspectives in MicroRNA Therapeutics for Cystic Fibrosis.

Noncoding RNA

January 2025

Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, University of Ferrara, 44121 Ferrara, Italy.

The discovery of the involvement of microRNAs (miRNAs) in cystic fibrosis (CF) has generated increasing interest in the past years, due to their possible employment as a novel class of drugs to be studied in pre-clinical settings of therapeutic protocols for cystic fibrosis. In this narrative review article, consider and comparatively evaluate published laboratory information of possible interest for the development of miRNA-based therapeutic protocols for cystic fibrosis. We consider miRNAs involved in the upregulation of CFTR, miRNAs involved in the inhibition of inflammation and, finally, miRNAs exhibiting antibacterial activity.

View Article and Find Full Text PDF

Antimicrobial peptides (AMPs) are key components of innate immunity across all domains of life. Natural and synthetic AMPs are receiving renewed attention in efforts to combat the antimicrobial resistance (AMR) crisis and the loss of antibiotic efficacy. The gram-negative pathogen Pseudomonas aeruginosa is one of the most concerning infecting bacteria in AMR, particularly in people with cystic fibrosis (CF) where respiratory infections are difficult to eradicate and associated with increased morbidity and mortality.

View Article and Find Full Text PDF

Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery.

NPJ Antimicrob Resist

November 2024

College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK.

Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus, whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M.

View Article and Find Full Text PDF

Mycobacterium abscessus complex (MABSC) comprises a group of environmental microorganisms, which are a concerning cause of opportunistic respiratory infections in patients with cystic fibrosis or bronchiectasis. Only 45.6% of MABSC treatments are successful, and therefore this is a need to discover new antimicrobials that can treat these pathogens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!